Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
Indaptus Therapeutics, Inc. (INDP)
Company Research
Source: GlobeNewswire
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced a clinical supply agreement with BeiGene. Building on Indaptus’ preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete cancer regressions and immunological memory in animal models, Indaptus plans to advance human clinical evaluation of the combination of BeiGene's anti-PD-1 antibody, tislelizumab, with Indaptus’ Decoy20, a novel treatment designed to induce a broad immune response to fight cancer. Indaptus’ Decoy
Show less
Read more
Impact Snapshot
Event Time:
INDP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INDP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INDP alerts
High impacting Indaptus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INDP
News
- Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its price target lowered by analysts at Maxim Group from $8.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in ImmunologyGlobeNewswire
- Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual MeetingGlobeNewswire
- Indaptus Therapeutics to Present at Two Upcoming Investor ConferencesGlobeNewswire
INDP
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 10/22/24 - Form 8-K
- INDP's page on the SEC website